Side-by-side · Research reference

LiraglutidevsProstamax

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedFlagship14/45 cited

BAnimal-MechanisticHUMAN-REVIEWED11/38 cited

Liraglutide

Daily GLP-1 RA · FDA-Approved

0.6–3.0 mgDaily doseSAXENDA (liraglutide) injectio 2014

5–10%Body-weight ↓SAXENDA (liraglutide) injectio 2014

~13 hrHalf-lifeSAXENDA (liraglutide) injectio 2014

SQ · Abdomen / thigh / arm · Once daily

Prostamax

Khavinson Bioregulator · Tissue-Specific Peptide

0.05 ng/mLActive concentrationZakutskiĭ 2006

2.5×SCE frequency increaseDzhokhadze 2012

4 AAPeptide length

SQ · Protocol per Khavinson tradition

01Mechanism of Action

Parameter

Liraglutide

Prostamax

Primary target

GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014

Chromatin in prostatic cells — pericentromeric heterochromatin regions

Pathway

GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014 Marso 2016

Epigenetic modulation → heterochromatin decondensation → transcriptional derepressionDzhokhadze 2012

Downstream effect

Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016

Increased sister chromatid exchange, Ag-NOR activation, reduced C-heterochromatin condensation; tissue-specific regenerative stimulation in prostate organotypic culturesDzhokhadze 2012 Zakutskiĭ 2006

Feedback intact?

Glucose-dependent insulin release preserves physiological feedback

—

Origin

Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014

Synthetic tetrapeptide modeled on naturally occurring protein-derived bioregulators isolated between lysine-arginine motifs in long-lived speciesKhavinson 2017

Antibody development

—

02Dosage Protocols

Parameter

Liraglutide

Prostamax

Standard dose (T2D, Victoza)

1.2–1.8 mg / daySAXENDA (liraglutide) injectio 2014

—

Standard dose (weight, Saxenda)

3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014

—

Frequency

Once daily, same time each day

—

Titration schedule

0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks

Mitigates GI side effects.

—

Evidence basis

FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016 SAXENDA (liraglutide) injectio 2014

Animal / organotypic cultureZakutskiĭ 2006 Dzhokhadze 2012

No randomized controlled trials in humans.

Duration

Indefinite for chronic indication

Not specified

Khavinson protocols typically 10–20 days per cycle; no long-term safety data.

Reconstitution

Pre-filled commercial pen (no reconstitution)

—

Timing

Any time of day; consistent

—

Half-life

~13 hrSAXENDA (liraglutide) injectio 2014

—

Effective concentration (in vitro)

—

0.05 ng/mLZakutskiĭ 2006

Organotypic culture model; demonstrated tissue-specific stimulation.

Human clinical dose

—

Not established

No published human trials; dosing extrapolated from Russian clinical tradition (not peer-reviewed).

Age groups studied

—

Young (3-week) and aged (18-month) rats; elderly humans (75–86 years) in vitroZakutskiĭ 2006 Dzhokhadze 2012

04Side Effects & Safety

Parameter

Liraglutide

Prostamax

GI symptoms

Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014

—

Pancreatitis risk

Rare; discontinue if suspected

—

Thyroid C-cell tumours

Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014

—

Hypoglycemia

Low risk as monotherapy; elevated with sulfonylureas / insulin

—

Heart rate

Modest ↑ resting HR (~2-3 bpm)

—

Cardiovascular benefit

↓ MACE in high-risk T2D (LEADER trial)Marso 2016

—

Pregnancy / OB

Contraindicated

—

Published adverse events

—

None reported in available literature

Genotoxicity signals

—

Increased sister chromatid exchange (SCE) — marker of DNA recombination/repair; unclear long-term implications

Metal ion interactions

—

Modulates Cu(II) and Cd(II) chromatin effects; unknown clinical relevance

Human safety data

—

Absent — no published Phase 1/2/3 trials

Absolute Contraindications

Liraglutide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to liraglutide

Prostamax

·Active prostate malignancy — epigenetic modulation effects unknown in cancer

Relative Contraindications

Liraglutide

·Severe gastroparesis
·History of pancreatitis
·Severe gastrointestinal disease

Prostamax

·History of prostate cancer — theoretical concern re: transcriptional activation
·Undiagnosed prostatic nodules or elevated PSA

05Administration Protocol

Parameter

Liraglutide

Prostamax

1. Reconstitution / device

Commercial pre-filled pen, no reconstitution required.

Subcutaneous or intramuscular — per Khavinson bioregulator tradition. No published human pharmacokinetic data.

2. Injection site

SQ — abdomen, thigh, or upper arm. Rotate sites.

If lyophilised: reconstitute with sterile water per manufacturer protocol (not standardized in literature).

3. Timing

Once daily, same time each day. Take with or without food.

Typically daily or every-other-day in Russian clinical tradition; duration 10–20 days per cycle.

4. Storage

Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.

No established biomarkers. Theoretical: PSA, prostate imaging, symptom scores (IPSS for BPH).

5. Needle

Pen-supplied 32G needle.

All protocols derived from non-peer-reviewed Russian clinical practice; Western regulatory approval absent.